CHAIN Biotech is a UK SME developing a new class of therapeutic based on a proprietary and highly differentiated CADDTM platform. The technology is based on living bacteria that have been engineered to deliver and produce specific bioactives in the lower gastrointestinal tract impacting on the gut microbiota and gut mucosa. The platform has significant patient, societal and cost benefits as well as broad clinical applicability i.e. treating infectious disease, inflammation and immunomodulation.